Expanding drug therapy options for menopausal syndrome in patients with breast cancer

Objective. To study the effect of allogeneic placental therapy with Melsmon® on the quality of life of breast cancer (BC) patients with assessing possible risks of disease recurrence. Patients and methods. This study included 71 patients of reproductive age (38.3 ± 5.5 years) with invasive BC without signs of cancer grade 2–3 after complex treatment. All patients had a moderate-to-severe form of menopausal syndrome (MS). All women were divided into two groups: Group I (study group, n = 33), in which human placenta hydrolysate (Melsmon®/Melsmon) was used to relieve menopausal symptoms; in group II (comparison group, n = 38), therapy with sedatives, vitamins, and phytotherapy were used. Allogeneic placental therapy with Melsmon® was used for 4 weeks (2 mL subcutaneously every other day (3 times a week)), then all patients received maintenance dosage: 2 mL subcutaneously twice a week for 8 weeks (total course of treatment was 12 weeks). Results. The study group (Melsmon®-therapy) showed a 3-fold decrease in vegetative disorders after 12 weeks, while this change was not observed in group II. There was a marked improvement in sleep quality in women in group I. The analysis of the stressors included in the approval list of the used psychodiagnostic method showed that stress reactions of respondents in group I in the form of anxiety, irritability, worries about uncontrollable life events, loss of confidence in the ability and possibility to solve personal problems were significantly lower than those in the women included in group II. During Melsmon®-therapy, positive dynamics of lipid profile in patients in group I was observed. Overall, a 1.8-fold decrease in triglyceride levels and 1.8- fold decrease in low-density lipoprotein levels were found in group I, with a 1.3-fold increase in high-density lipoproteins secretion. Conclusion. The results demonstrated the efficacy of MS treatment with human placenta hydrolysate, which contributed to a pronounced reduction in vegetative, metabolic, and psychological manifestations of MS. No recurrence of breast cancer was detected during the therapy period to date. The use of Melsmon®-therapy can expand the possibilities of drug therapy to improve the quality of life in menopausal breast cancer patients. © 2022, Dynasty Publishing House. All rights reserved.